# Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer

> **NCT05544227** · PHASE1 · COMPLETED · sponsor: **Williams Cancer Foundation** · enrollment: 15 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** SV-102

## Key facts

- **NCT ID:** NCT05544227
- **Lead sponsor:** Williams Cancer Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-01
- **Primary completion:** 2024-12-10
- **Final completion:** 2025-06-01
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05544227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05544227, "Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05544227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*